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Adherence to treatment is imperative to achieve and maintain suppression of the hepatitis B virus 
(HBV). To date, there has been limited research on what defines adherence to HBV therapies. Our 
study aimed to investigate the relationship between missed days of anti-viral therapy and HBV DNA 
virological breakthrough. 
Methods 
In 2014 277 patients receiving anti-viral therapies in three Sydney tertiary hospitals completed a 
cross-sectional survey. Data were excluded from analyses if participants reported factors known to 
affect HBV DNA viral suppression (n=66) or if HBV virology results were not available (n=7). Self-
reported non-adherence was assessed as 0 to > 6 single days of treatment missed and 2 to 6 
consecutive days missed in the last 30 days. Associations between missed days and virological 
breakthrough (defined as > 10-fold rise in serum HBV DNA above nadir or after achieving virological 
response in the last 12 months) were examined to determine the level of non-adherence most 
strongly associated with virological breakthrough.  Associations were summarised as odds ratios (OR) 
and relative risks (RR). 
Results  
Of the 204, 32 participants (15.6%) had quantifiable HBV DNA levels (> 20 IU/mL), with 15 (46.8%) of 
these participants experiencing virological breakthrough. Participants reported never missing 
medication (n=130, 63.7%), missing one day (n=23, 11.3%), missing >one day (n=23, 11.3%) and 
missing >2-6 days (n=15, 7.3%) and missing >6 days (n=13, 6.4%). The most discriminating definition 
of non-adherence was missing > one day of medication (RR=8.3; OR=10.2, 95%CI: 3.1-33.8, 
p≤0.001, ROC 0.76) and sensitivity and specificity of detecting the outcome of 73.3% and 78.8%.   
Conclusion 
This study produced an evidence-based definition of non-adherence that informs clinical practice, in 
that patients reporting missing >1 day of medication in the previous 30 days have an increased risk of 
virological breakthrough, and provides the basis for key patient education messages. 
 
 
